Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Publication/Presentation Date
3-2021
Volume
39
Issue
6
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS